BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

DiaSorin Receives Clearance For LIAISON(R) 25-OH Vitamin D And Parathyroid Hormone Assays


10/19/2005 5:10:02 PM

STILLWATER, Minn., Feb. 17 /PRNewswire/ -- DiaSorin Inc. announced Friday, February 13, that it received Food and Drug Administration clearance for the Company's LIAISON(R) 25-hydroxy Vitamin D and LIAISON(R) N-TACT(TM) PTH Assays. The Company will begin immediate placement of its LIAISON(R) random- access chemiluminescent analyzer in hospitals and clinical reference laboratories nationwide. Testing for 25-hydroxy Vitamin D and PTH provides the physician with definitive analysis of nutritional Vitamin D deficiency, an acute concern in the elderly and in individuals with dark complexions.

"We are proud to be the leader in bone and mineral diagnostics with the introduction of DiaSorin's third generation of 25-hydroxyvitamin D testing, a LIAISON(R) chemiluminescence assay," said Stephen P. Gouze, President and General Manager of DiaSorin Inc. "LIAISON(R) offers the only antibody-based Vitamin D assay available in an automated, random access chemiluminescence platform, providing the same consistent results physicians have seen from DiaSorin's radioimmunoassay for over a decade. Patients benefit from the rapid results (35 minutes to first result) and world class-assay reliability of the LIAISON(R) system. Laboratories benefit from high throughput (180 tests per hour) and complete walk-away automation from extraction through data output."

Over 800 LIAISON(R) systems are in use worldwide with a menu of over 50 diagnostic tests including hepatitis, infectious disease and autoimmune assays. DiaSorin will be adding these and other assays in the United States as FDA clearance is received.

DiaSorin has a worldwide workforce of over 500 employees with corporate headquarters in Saluggia, Italy. U.S. operations, located in Stillwater, Minnesota, include research and development, sales, and ISO 9001-registered manufacturing facilities.

DiaSorin Inc.

CONTACT: Rebecca Aistrup, Director of Marketing of DiaSorin Inc.,+1-651-351-5735


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->